Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major

Abstract

Oral deferiprone induces sustained decreases in body iron to concentrations compatible with the avoidance of complications from iron overload. The risk of agranulocytosis associated with deferiprone may restrict its administration to patients who are unable or unwilling to use deferoxamine.